Vericel (VCEL) EBITDA Margin (2011 - 2026)
Vericel (VCEL) posted EBITDA Margin of 0.56% for Q2 2026, up 104.75% sequentially from 11.79% in Q1 2026, and up 377.0% YoY from 0.12% in Q2 2025.
Analysis
Vericel (VCEL) EBITDA Margin (2011 - 2026) Analysis & Trends
Vericel has reported EBITDA Margin for 16 years, with the latest figure at 0.56% in Q2 2026.
- Quarterly EBITDA Margin rose 377.0% year-over-year to 0.56% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 5.95% (up 547.0% YoY) and the FY2025 annual result came in at 4.0%, up 209.0% from the prior year.
- EBITDA Margin grew to 0.56% in Q2 2026 per VCEL's latest filing, from 11.79% in the prior quarter.
- Over five years, EBITDA Margin peaked at 24.52% in Q4 2024 and troughed at 24.52% in Q2 2022.
- A 5-year average of 4.81% and a median of 10.87% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2026: EBITDA Margin tumbled 1508 bps in 2022, then soared 1254 bps in 2026.
- Over 5 years, EBITDA Margin stood at 11.55% in 2022, then surged by 70 bps to 19.59% in 2023, then grew by 25 bps to 24.52% in 2024, then slipped by 2 bps to 24.12% in 2025, then slumped by 98 bps to 0.56% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 0.56%, 11.79%, and 24.12% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 0.56% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.56% |
| Mar 31, 2026 | -11.79% |
| Dec 31, 2025 | 24.12% |
| Sep 30, 2025 | 5.11% |
| Jun 30, 2025 | -3.21% |
| Mar 31, 2025 | -24.32% |
| Dec 31, 2024 | 24.52% |
| Sep 30, 2024 | -4.26% |
| Jun 30, 2024 | -11.45% |
| Mar 31, 2024 | -10.66% |
| Dec 31, 2023 | 19.59% |
| Sep 30, 2023 | -11.09% |
| Jun 30, 2023 | -12.98% |
| Mar 31, 2023 | -19.94% |
| Dec 31, 2022 | 11.55% |
| Sep 30, 2022 | -17.61% |
| Jun 30, 2022 | -24.52% |
| Mar 31, 2022 | -20.16% |
| Dec 31, 2021 | 8.70% |
| Sep 30, 2021 | -14.38% |